These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 10081849)

  • 1. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.
    Sánchez-Carbayo M; Herrero E; Megias J; Mira A; Espasa A; Chinchilla V; Soria F
    J Urol; 1999 Apr; 161(4):1110-5. PubMed ID: 10081849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma.
    Pariente JL; Bordenave L; Michel P; Latapie MJ; Ducassou D; Le Guillou M
    J Urol; 1997 Aug; 158(2):338-41. PubMed ID: 9224298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer.
    Pariente JL; Bordenave L; Jacob F; Gobinet A; Leger F; Ferriere JM; Le Guillou M
    J Urol; 2000 Apr; 163(4):1116-9. PubMed ID: 10737478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
    Bian W; Xu Z
    Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer.
    Sánchez-Carbayo M; Urrutia M; González de Buitrago JM; Navajo JA
    Clin Cancer Res; 2000 Sep; 6(9):3585-94. PubMed ID: 10999749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
    Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
    Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma.
    Hakenberg OW; Fuessel S; Richter K; Froehner M; Oehlschlaeger S; Rathert P; Meye A; Wirth MP
    Urology; 2004 Dec; 64(6):1121-6. PubMed ID: 15596183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
    el-Ahmady O; Halim AB; el-Din AG
    Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
    Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
    J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
    Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of bladder cancer by analysis of urinary fibronectin.
    Menéndez V; Fernández-Suárez A; Galán JA; Pérez M; García-López F
    Urology; 2005 Feb; 65(2):284-9. PubMed ID: 15708039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
    Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
    Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
    J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer.
    D'Hallewin MA; Baert L
    J Urol; 1996 Feb; 155(2):475-6. PubMed ID: 8558639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.